Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies

Annals of the New York Academy of Sciences

Volumn 1263, Issue 1, 2012, Pages 43-56

  Gupta, Ira V ^a   Jewell, Roxanne C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

B NHL; CD20; CLL; Monoclonal antibody; Ofatumumab

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; OFATUMUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INFECTION; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PNEUMONIA; POLYNEUROPATHY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SORE THROAT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84864748652     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06661.x     Document Type: Article

References (62)

1. NCCN. "NCCN Clinical Practice Guidelines in Oncology. NCCN Non-Hodgkin's lymphoma Guidelines Vers 2, "NCCN. Available at: Accessed 22 March 2012.
2. SEER. "Stat Fact Sheets: Chronic Lymphocytic Leukemia, "Surveillance Epidemiology and End Results. Available at: Accessed 22 March 2012.
3. SEER. "Fast Stats: Chronic Lymphocytic Leukemia Prevalence, "Surveillance Epidemiology and End Results. Available at: Accessed 22 March 2012.
4. SEER. "Stat Fact Sheets: Non-Hodgkin Lymphoma, "Surveillance Epidemiology and End Results. Available at: Accessed 22 March 2012.
5. ACS. "Detailed Guide: 'What Is Non-Hodgkin Lymphoma?', "American Cancer Society. Available at: Accessed 22 March 2012.
6. Osterborg, A. 2010. Ofatumumab, a human anti-CD20 monoclonal antibody. Expert. Opin. Biol. Ther. 10: 439-449.
7. NCCN. "NCCN Clinical Practice Guidelines in Oncology. NCCN Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma Guidelines Vers 1, "NCCN. Available at: Accessed 22 March 2012.
8. Genentech. "Rituxan (rituximab) prescribing information." Available at: Accessed 25 February 2012.
9. GlaxoSmithKline. "Arzerra (ofatumumab) prescribing information." Available at: Accessed 25 February 2012.
10. GlaxoSmithKline. "Bexxar (tositumomab and iodine I 131 tositumomab) prescribing information." Available at: Accessed 4 April 2012.
11. Spectrum Pharmaceuticals Inc. "Zevalin (ibritumomab tiuxetan) prescribing information." Available at: Accessed 4 April 2012.
12. Genzyme. "Campath (alemtuzumab) prescribing information." Available at: Accessed 25 February 2012.
13. Cheson, B.D. 2010. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28: 3525-3530.
14. Teeling, J.L. et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177: 362-371.
15. Teeling, J.L. et al. 2004. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
16. Pawluczkowycz, A.W. et al. 2009. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 183: 749-758.
17. 2010. Ofatumumab (Arzerra) for CLL. Med. Lett. Drugs Ther. 52: 51-52.
18. Bello, C., M. Veliz & J. Pinilla-Ibarz. 2011. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Expert Rev. Clin. Immunol. 7: 295-300.
19. Czuczman, M.S. & S.A. Gregory. 2010. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk. Lymphoma 51: 983-994.
20. Nabhan, C. & N.E. Kay. 2011. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clin. Med. Insights 5: 45-53.
21. Nightingale, G. 2011. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann. Pharmacother. 45: 1248-1255.
22. O'Brien, S. & A. Osterborg. 2010. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk. 10: 361-368.
23. Reagan, J.L. & J.J. Castillo. 2011. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 11: 151-160.
24. Robak, T. & E. Robak. 2011. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 25: 13-25.
25. Sanford, M. & P.L. McCormack. 2010. Ofatumumab. Drugs 70: 1013-1019.
26. Tsimberidou, A.M. 2010. Ofatumumab in the treatment of chronic lymphocytic leukemia. Drugs Today (Barc) 46: 451-461.
27. Zhang, B. 2009. Ofatumumab. mAbs 1: 326-331.
28. Coiffier, B. et al. 2008. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111: 1094-1100.
29. Wierda, W.G. et al. 2010. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28: 1749-1755.
30. Wierda, W.G. et al. 2010. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Presented at the 52nd Annual Meeting of the American Society of Hematology, Orlando. Blood 116. Abstract 921 (oral presentation).
31. O'Brien, S.M. et al. 2003. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98: 2657-2663.
32. Keating, M.J. et al. 2002. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554-3561.
33. Wierda, W.G. et al. 2011. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118: 5126-5129.
34. GlaxoSmithKline. "GSK and Genmab receive accelerated approval for Arzerra™, "news release, April 19, 2010, October 26, 2009. Available at: Accessed 5 April 2012.
35. GlaxoSmithKline. "GlaxoSmithKline receives conditional marketing authorization in the EU for Arzerra® (ofatumumab), "news release, April 19, 2010. Available at: Accessed 5 April 2012.
36. Wierda, W.G. et al. 2011. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117: 6450-6458.
37. Hallek, M. et al. 2010. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164-1174.
38. Keating, M.J. et al. 2005. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23: 4079-4088.
39. Tam, C.S. et al. 2008. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112: 975-980.
40. Hagenbeek, A. et al. 2008. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111: 5486-5495.
41. Czuczman, M.S. et al. 2012 Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119: 3698-3704.
42. Czuczman, M.S. et al. 2012. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br. J. Haematol. 157: 438-445.
43. Coiffier, B. et al. 2010. Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multicenter phase II study. Presented at the 52nd Annual Meeting of the American Society of Hematology, Orlando. Blood 116. Abstract 3955 (poster presentation).
44. Matasar, M.J. et al. 2011. A phase II study of ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory aggressive B-cell lymphoma prior to autologous stem cell transplantation (ASCT). Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego. Blood 118. Abstract 957 (oral presentation).
45. Gisselbrecht, C. et al. 2010. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28: 4184-4190.
46. Furman, R.R. et al. 2011. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia. Presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego. Blood 118. Abstract 3701 (poster presentation).
47. Coiffier, B. et al. 2010. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br. J. Haematol. 150: 58-71.
48. GlaxoSmithKline. Data on file.
49. Österborg, A. et al. 2009. Correlation between serum ofatumumab concentrations, baseline patient characteristics and clinical outcomes in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) treated with single-agent ofatumumab. Presented at the 51st Annual Meeting of the American Society of Hematology, New Orleans. Blood 114. Abstract 3433 (poster presentation).
50. Ostergaard, M. et al. 2010. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 62: 2227-2238.
51. GlaxoSmithKline. "Investigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (RA) patients who had an inadequate response to TNF-α antagonist." Available at: Accessed 22 March 2012.
52. GlaxoSmithKline. "Investigating clinical efficacy of ofatumumab in adult rheumatoid arthritis (RA) patients who had an inadequate response to methotrexate therapy." Available at: Accessed 22 March 2012.
53. GlaxoSmithKline. "Ofatumumab dose-finding in relapsing remitting multiple sclerosis patients." Available at: Accessed 22 March 2012.
54. GlaxoSmithKline. "A single-arm, international, multi-center trial investigating the efficacy and safety of ofatumumab retreatment and maintenance in CLL patients who progressed following response or stable disease after ofatumumab treatment in Hx-CD20-406." Available at: Accessed 22 March 2012.
55. GlaxoSmithKline. "A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy (PROLONG)." Available at: Accessed 5 April 2012.
56. GlaxoSmithKline. "An open label, multicenter study investigating the safety and efficacy of ofatumumab therapy versus physicians' choice in patients with bulky fludarabine-refractory chronic lymphocytic leukaemia (CLL)." Available at: Accessed 22 March 2012.
57. GlaxoSmithKline. "A phase II, multi-centre study investigating the safety and efficacy of ofatumumab and bendamustine combination in patients with untreated or relapsed chronic lymphocytic leukaemia (CLL)." Available at: Accessed 22 March 2012.
58. GlaxoSmithKline. "A phase III, open label, randomized, multicenter trial of ofatumumab added to chlorambucil versus chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia (COMPLEMENT 1)." Available at: Accessed 22 March 2012.
59. GlaxoSmithKline. "A phase III, open label, randomized trial of ofatumumab added to fludarabine-cyclophosphamide vs. fludarabine-cyclophosphamide combination in subjects with relapsed chronic lymphocytic leukemia (COMPLEMENT 2)." Available at: Accessed 22 March 2012.
60. GlaxoSmithKline. "Phase III randomized, open label study of single agent ofatumumab versus single agent rituximab in follicular lymphoma relapsed after rituximab-containing therapy (HOMER)." Available at: Accessed 22 March 2012.
61. GlaxoSmithKline. "A randomized, open label study of ofatumumab and bendamustine combination therapy compared with bendamustine monotherapy in indolent B-cell non-Hodgkin's lymphoma unresponsive to rituximab or a rituximab-containing regimen during or within six months of treatment (COMPLEMENT A+B)." Available at: Accessed 22 March 2012.
62. GlaxoSmithKline. "Ofatumumab versus rituximab salvage chemoimmunotherapy followed by autologous stem cell transplant in relapsed or refractory diffuse large B cell lymphoma (ORCHARRD)." Available at: Accessed 22 March 2012.